Aisling Capital Mergers and Acquisitions Summary

Private Equity Firm Profile

Aisling Capital’s most common sectors for investment arelife science (79%) and medical products (13%) . The Firm’s most common investment types include venture (53%) and pipe (25%). In total, Aisling Capital has invested in 14 US states and 4 different countries. Its largest (disclosed) acquisition occurred in 2007 when it acquired Catalent for $3.3B.

In the last 3 years, Aisling Capital has exited 2 companies. The Firm’s most common exit type is trade sale (69%). Aisling Capital’s largest (disclosed) exit occurred in 2017 when it sold ZELTIQ Aesthetics for $2.5B.

Join Mergr to view Aisling Capital’s full profile and discover more large private equity firm investors just like it.

M&A Summary

  • M&A Total Activity91
    • M&A Buy Activity57
    • M&A Sell Activity34
  • Total Sectors Invested 6
  • Total Countries Invested 4
  • M&A Buy/Sell Connections 32
  • M&A Advisors 3

Aisling Capital

888 Seventh Avenue, 12th Floor,
New York, New York 10106
United States
(212) 651-6380
www.aislingcapital.com
dpurcell@aislingcapital.com

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products

Target Transaction Types: Buyout (LBO, MBO, MBI), PIPE, Stake Purchase, Venture

Geographic Preferences: East US, Midwest US, South US, West US

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size 20 50
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (1.0/yr) # 52 5 - - - - 57
vol $6.4B $6.4B
Sell (0.8/yr) # 31 2 1 1 - - 35
vol $8.6B $8.6B
  92

Most Recent M&A

Company Date Value Type
Medical Knowledge Group LLC 2022-01-03 - Secondary Sale
New York, New York · www.mkgny.com
Monte Rosa Therapeutics GmbH 2020-11-24 - Venture
Boston, Massachusetts · www.monterosatx.com
Talaris Therapeutics, Inc. 2020-10-06 - Venture
Boston, Massachusetts · www.talaristx.com
Eidos Therapeutics, Inc. 2020-10-05 - Trade Sale
San Francisco, California · www.eidostx.com
Aimmune Therapeutics, Inc. 2020-08-31 - Trade Sale
Brisbane, California · www.aimmune.com
Spruce Biosciences, Inc. 2020-02-19 - PIPE
Daly City, California · www.sprucebiosciences.com
Medical Knowledge Group LLC 2020-01-08 - Recapitalization
New York, New York · www.mkgny.com
Syndax Pharmaceuticals, Inc. 2020-01-01 - PIPE
Waltham, Massachusetts · www.syndax.com
Nuvation Bio, Inc. 2019-10-28 - Venture
New York, New York · www.nuvationbio.com
Elevation Oncology, Inc. 2019-01-01 - Venture
New York, New York · www.elevationoncology.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 21 (95%) - 45 (79%) 6.4B (100%)
Medical Products - - 7 (12%) 24M (< 1%)
Consumer Products - - 2 (4%) -
Business Services 1 (5%) - 1 (2%) -
Healthcare Services - - 1 (2%) -
Information Technology - - 1 (2%) -
Total 22 - 57 $6.4B

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 19 (86%) - 53 (93%) 6.4B (100%)
  California 7 (32%) - 16 (28%) -
  Massachusetts 4 (18%) - 8 (14%) -
  New York 2 (9%) - 6 (11%) -
  New Jersey 1 (5%) - 5 (9%) 3.3B (52%)
  North Carolina - - 5 (9%) 3.0B (47%)
  Florida - - 3 (5%) 69M (1%)
  Texas 2 (9%) - 2 (4%) -
  Pennsylvania 2 (9%) - 2 (4%) -
  Wisconsin 1 (5%) - 1 (2%) -
  Virginia - - 1 (2%) -
  Ohio - - 1 (2%) -
  Kentucky - - 1 (2%) -
  Connecticut - - 1 (2%) -
  Colorado - - 1 (2%) -
Switzerland 1 (5%) - 2 (4%) -
Australia 1 (5%) - 1 (2%) -
Ireland 1 (5%) - 1 (2%) -
Domestic 19 (86%) - 53 (93%) 6.4B (100%)
Cross-border 3 (14%) - 4 (7%) -
Total 22 - 57 $6.4B

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture 9 (41%) - 30 (53%) 45M (1%)
PIPE 12 (55%) - 14 (25%) -
Buyout (LBO, MBO, MBI) - - 5 (9%) -
Stake Purchase 1 (5%) - 4 (7%) -
Recapitalization - - 2 (4%) 3.0B (47%)
Divestiture - - 1 (2%) 3.3B (52%)
Growth Capital - - 1 (2%) 24M (< 1%)
Total 22 - 57 $6.4B

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 13 (37%) 7.5B (87%)
Trade Sale 11 (31%) 1.1B (13%)
IPO 9 (26%) -
Secondary Sale 1 (3%) -
SPAC 1 (3%) -
Total 35 $8.6B

Top M&A Advisors

Financial Deals
Stifel, Nicolaus & Co., Inc.
1
J.P. Morgan Securities
1
Legal Deals
Morgan, Lewis & Bockius LLP
1

Deal Values

buy # Total
> $1B 2 $6.3B
< $100M 2 $69M
TOTAL $6.4B
Largest Catalent, Inc.
$3.3B (2007-01-25)
sell # Total
> $1B 3 $5.8B
$100M to $1B 8 $2.8B
< $100M 1 $20M
TOTAL $8.6B
Largest ZELTIQ Aesthetics, Inc.
$2.5B (2017-02-13)

M&A Connections

Deals
Acquired from
Investor(s)
4%
2 (4%)
Strategic(s)
2%
1 (2%)
Exited to
Investor(s)
3%
1 (3%)
Strategic(s)
69%
24 (69%)

FAQ

When was Aisling Capital founded?

Aisling Capital was founded in 2000.

What type of investor is Aisling Capital?

Aisling Capital is a private equity firm.

Where is Aisling Capital headquartered?

Aisling Capital is headquartered in New York, New York.

How much capital does Aisling Capital have under management?

Aisling Capital has 1.8B USD under management.

 Subscribe to unlock this and 199,513
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 190K M&A Transactions
  • 195K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.